Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Plasmodium falciparum | plasmepsin II | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Wolbachia endosymbiont of Brugia malayi | malonyl-CoA decarboxylase | 0.2155 | 1 | 0.5 |
Schistosoma mansoni | subfamily A1A unassigned peptidase (A01 family) | 0.0088 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.2155 | 1 | 1 |
Trichomonas vaginalis | Clan AA, family A1, cathepsin D-like aspartic peptidase | 0.0088 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin I | 0.0088 | 0 | 0.5 |
Schistosoma mansoni | cathepsin D (A01 family) | 0.0088 | 0 | 0.5 |
Toxoplasma gondii | aspartyl proteinase (eimepsin), putative | 0.0088 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin II | 0.0088 | 0 | 0.5 |
Trypanosoma cruzi | malonyl-CoA decarboxylase, mitochondrial precursor, putative | 0.0847 | 0.3669 | 0.5 |
Plasmodium vivax | aspartyl proteinase, putative | 0.0088 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin IV | 0.0088 | 0 | 0.5 |
Toxoplasma gondii | aspartyl protease ASP1 | 0.0088 | 0 | 0.5 |
Leishmania major | malonyl-coa decarboxylase-like protein | 0.0847 | 0.3669 | 0.5 |
Plasmodium falciparum | plasmepsin VI | 0.0088 | 0 | 0.5 |
Echinococcus multilocularis | cathepsin d (lysosomal aspartyl protease) | 0.0088 | 0 | 0.5 |
Echinococcus granulosus | cathepsin d lysosomal aspartyl protease | 0.0088 | 0 | 0.5 |
Schistosoma mansoni | cathepsin D (A01 family) | 0.0088 | 0 | 0.5 |
Trypanosoma brucei | malonyl-CoA decarboxylase, mitochondrial precursor, putative | 0.0847 | 0.3669 | 0.5 |
Trypanosoma cruzi | malonyl-CoA decarboxylase, mitochondrial precursor, putative | 0.0847 | 0.3669 | 0.5 |
Plasmodium vivax | plasmepsin IV, putative | 0.0088 | 0 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.